IONS Ionis Pharmaceuticals, Inc.

37.93
0  -1%
Previous Close 38.14
Open 38.05
Price To book 46.57
Market Cap 4.69B
Shares 123,749,000
Volume 1,778,616
Short Ratio 10.03
Av. Daily Volume 2,016,730

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 17708580
  2. CT ORDER - Confidential treatment order 17693070
  3. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17651262
  4. 8-K - Current report 17644854
  5. 8-K - Current report 17616239

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 interim data released November 2016.
IONIS-ANGPTL3-LRx
Cardiovascular disease
Phase 1/2 ongoing
IONIS-DMPK-2.5Rx
Myotonic Dystrophy Type 1 (DM1)
Phase 3 data due 2Q 2017.
IONIS-TTRRx
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Approved December 23, 2016.
SPINRAZA - Nusinersen
Spinal muscular atrophy (SMA)
Phase 2 data released November 2016.
IONIS-FXIRx
End-stage renal disease
Phase 3 data released March 6, 2017 - primary endpoint met. Relative safety concerns noted.
Volanesorsen - APPROACH
Familial chylomicronemia syndrome (FCS)
Phase 2 data released 3Q 2015
IONIS-APO(a)Rx
High lipoprotein(a), or Lp(a)
Phase 2 data released January 4, 2016.
IONIS-GCGRRx
Type 2 diabetes
Phase 3 initiated November 2015
Volanesorsen
Partial lipodystrophy rapidly
Phase 2 released Feb 2015. Achieved statistically significant results but data released was as of 36 weeks rather than 27 weeks for the primary endpoint
IONIS-PTP1BRx
Type 2 diabetes
Phase 3 initiated November 2015
Volanesorsen
Familial partial lipodystrophy (FPL)
Partner GSK announced May 2016 decision not to be proceed with Phase 3 outcome trial
IONIS-TTRRx
CARDIO-TTR - Cardiomyopathy form of TTR amyloidosis.

Latest News

  1. Lifshitz & Miller LLP Announces Investigation of Air Methods Corporation, Fortress Investment Group LLC, Galena Biopharma, Inc., Ionis Pharmaceuticals, Inc., LMI Aerospace, Inc., Lumos Networks Corp., Silver Bay Realty Trust Corp. and Terra
  2. Recent Developments for Ionis Pharmaceuticals
  3. Ionis’s Subsidiary Akcea Therapeutics and Volanesorsen
  4. A Look at Ionis Pharmaceuticals’ Spinraza
  5. Understanding Ionis Pharmaceuticals’ 2016 Revenue Stream
  6. Ionis Pharmaceuticals’ Revenue in 2016
  7. Better Buy: Ionis Pharmaceuticals, Inc. vs. Juno Therapeutics
  8. AveXis Inc Stock Is Spiking Again Today -- Here's Why
  9. Could This Drug Help Ionis Stock Recover From a Disappointing 2016?
  10. Falling Biotechs: Cara Reports Zero Sales, Ionis Downgraded
  11. Why Ionis Pharmaceuticals Is Tumbling 10% Today
  12. Analysts' Actions -- Kimberly-Clark, IberiaBank, Ionis Pharma, Actuant and More
  13. Ionis Pharma downgraded by Goldman
  14. Why Ionis Pharmaceuticals Rallied 12% in February
  15. Ionis Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IONS-US : March 9, 2017
  16. SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Ionis Pharmaceuticals Inc. and Advises Investors with Losses to Contact the Firm
  17. Ionis Pharma Lipid Disorder Candidate Positive in Phase III
  18. Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal
  19. 3 Reasons You Need to Know About This Future Blockbuster From Ionis
  20. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation of Ionis Pharmaceuticals, Inc.